ストックスクリーナーアプリを入手
1.96
0.51%
-0.01
前日終値:
$1.97
開ける：
$1.99
24時間の取引高:
3.45M
Relative Volume:
0.90
時価総額：
$340.61M
収益：
$250.00K
当期純損益:
$-24.15M
株価収益率:
-1.8393
EPS:
-1.0656
ネットキャッシュフロー:
$-12.40M
1週間 パフォーマンス:
-6.67%
1か月 パフォーマンス:
+16.67%
6か月 パフォーマンス:
-1.51%
1年 パフォーマンス:
+151.28%
1日の値動き範囲:
$1.87
$1.99
1週間の範囲:
$1.87
$2.22
52週間の値動き範囲:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
名前
Palisade Bio Inc
セクター
電話
(858) 704-4900
住所
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.96 | 340.61M | 250.00K | -24.15M | -12.40M | -1.0656 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-09 | 開始されました | Wolfe Research | Outperform |
| 2026-03-26 | 開始されました | H.C. Wainwright | Buy |
| 2026-02-25 | 開始されました | Stifel | Buy |
| 2026-01-09 | 開始されました | B. Riley Securities | Buy |
| 2025-12-29 | 開始されました | Piper Sandler | Overweight |
Palisade Bio Inc (PALI) 最新ニュース
Enterprise value to revenue forward of Palisade Bio, Inc. – LS:A4098S - TradingView
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock By Investing.com - Investing.com Australia
Insider Buying: Robert Baltera Acquires 45,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Form 4 Palisade Bio Inc For: 10 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock - Investing.com UK
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - The Manila Times
Palisade Bio to present clinical updates at Lee... - Pluang
Palisade Bio leaders set to outline IBD drug plans at Boston forum - Stock Titan
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets - Seeking Alpha
Insider Buying: Robert Baltera Acquires 50,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio chief medical officer Jones sells $106,535 in stock By Investing.com - Investing.com Nigeria
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
Palisade Bio CEO, CFO Finley sells $303k in stock By Investing.com - Investing.com South Africa
Palisade Bio chief medical officer Jones sells $106,535 in stock - Investing.com
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock - Investing.com
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock By Investing.com - Investing.com Canada
Palisade Bio CEO, CFO Finley sells $303k in stock - Investing.com
Director at Palisade Bio (PALI) adds 50,000 shares in open-market buys - Stock Titan
[Form 4] PALISADE BIO, INC. Insider Trading Activity - Stock Titan
Palisade Bio (PALI) CEO Finley sells shares to cover RSU tax - Stock Titan
Insider Spends US$59k Buying More Shares In Palisade Bio - simplywall.st
Form 144 PALISADE BIO For: 7 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock - Investing.com
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock By Investing.com - Investing.com South Africa
Form 4 Palisade Bio Inc For: 6 July By Investing.com - Investing.com Canada
Palisade Bio (PALI) director adds 30,000 shares in open-market buys - Stock Titan
Price to book forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Stifel Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright reiterates Palisade Bio stock rating on FDA trial clearance - Investing.com South Africa
Enterprise value to revenue forward of Palisade Bio, Inc. – BOATS:PALI - TradingView
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? - Stocktwits
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2500 Growth Benchmark - marketscreener.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Index - marketscreener.com
Palisade Bio Receives FDA Clearance Of IND For PALI-2108 And Plans To Initiate Global Phase 2 ASCENTRA-UC Study In Ulcerative Colitis - marketscreener.com
Palisade Bio stock surges on FDA clearance for UC trial By Investing.com - Investing.com South Africa
Palisade Bio stock surges on FDA clearance for UC trial - Investing.com
Enterprise value to EBIT forward of Palisade Bio, Inc. – BOATS:PALI - TradingView
PALI Stock Climbs As Palisade Bio Loads Up Dealmakers - StocksToTrade
PALI Stock Grinds Higher As Pipeline And Board Upgrades Draw Trader Focus - timothysykes.com
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell 2000 Value Benchmark - marketscreener.com
Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial - Moomoo
Palisade Bio, Inc.(NasdaqCM: PALI) added to Russell Microcap Value Benchmark Index - marketscreener.com
Palisade Bio receives FDA clearance for ulcerative colitis trial By Investing.com - Investing.com South Africa
Palisade Bio receives FDA clearance for ulcerative colitis trial - Investing.com
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis - The Manila Times
Palisade Bio Inc (PALI) 財務データ
収益
当期純利益
現金流量
EPS
Palisade Bio Inc (PALI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Baltera Robert Jr. | Director |
Jul 08 '26 |
Buy |
1.99 |
20,000 |
39,798 |
436,904 |
| Baltera Robert Jr. | Director |
Jul 07 '26 |
Buy |
2.03 |
30,000 |
61,044 |
416,904 |
| Baltera Robert Jr. | Director |
Jul 06 '26 |
Buy |
2.05 |
20,000 |
41,040 |
386,904 |
| Jones Mitchell Lawrence | Chief Medical Officer |
Jul 07 '26 |
Sale |
2.05 |
51,880 |
106,536 |
94,009 |
| Finley John David | CEO, CFO |
Jul 07 '26 |
Option Exercise |
0.70 |
133 |
93 |
217,688 |
| Finley John David | CEO, CFO |
Jul 07 '26 |
Sale |
2.07 |
146,798 |
303,343 |
217,555 |
2.64%
大文字化:
|
ボリューム (24 時間):